Schott Pharma stock softens after recent gains as Xetra price dips to 23 euros

Schott Pharma (ISIN DE000A3ENQ51) stock traded at 23.00 EUR on Xetra on September 2, 2026, down about 0.6% in early trading compared with the previous close according to data cited by finanzen.net. Market data show that the share also marked an intraday low at 23.00 EUR in the same session, after having opened at that level.

Schott Pharma stock under mild pressure on Xetra

According to intraday Xetra figures compiled on September 2, 2026, Schott Pharma shares were among the weaker names in German trading, with the price slipping 0.4% to 23.05 EUR around midday in one snapshot and 0.6% to 23.00 EUR around the opening auction. One Xetra overview highlights that the stock opened at 23.00 EUR and traded slightly lower by 12:28 local time, indicating modest profit taking after recent strength.

A separate price snapshot for September 1, 2026 from the Duesseldorf exchange shows Schott Pharma quoted at 23.30 EUR at 16:30 local time, corresponding to a gain of 3.10% versus the previous close, with intraday Xetra trading that day ranging between 23.20 EUR and 23.55 EUR. This overview underlines that the stock had been trading near the upper end of the 23 euro range before the latest consolidation.

Recent quarterly figures show double digit revenue growth

Investors are still digesting the latest quarterly update, in which Schott Pharma reported clear revenue growth and raised its outlook for the current financial year. According to recent summaries of the third business quarter, group revenue increased by a double digit percentage compared with the same period a year earlier, while operating earnings expanded at an even faster rate. In that update, the company also lifted its revenue and earnings guidance for the full year, signaling confidence in demand for its pharmaceutical packaging and delivery systems.

In the same context, market commentary highlighted that the improvement in operating profitability outpaced the top line, implying a margin expansion versus the prior year quarter. For investors, this combination of higher revenue and better margins is a key argument behind the recent share price gains. Historical figures from fiscal year 2023 are now mainly relevant as a comparison base rather than as a current performance indicator.

Parenteral packaging remains at the core of the business

One of Schott Pharma's core product areas is high quality glass and polymer systems for injectable drugs, including ready to use vials, prefillable syringes and cartridges for parenteral applications. In recent reporting, management emphasized that demand for advanced drug delivery systems for biologics and other complex therapies continues to grow, supported by new product launches by pharmaceutical clients and the trend toward self administration.

Schott Pharma stock: current price level for investors

As of September 2, 2026, Schott Pharma stock traded around 23.00 EUR on Xetra, slightly below the 23.30 EUR level seen on the Duesseldorf exchange at the close on September 1, 2026, when the share had advanced 3.10% on that venue. For retail investors following German trading venues, this places the company in the mid 20 euro range, with recent price action shaped by both upgraded guidance and normal short term volatility.

Schott Pharma key data

• Company: Schott Pharma AG & Co. KGaA
• ISIN: DE000A3ENQ51
• Ticker: UNV
• Trading venue: Xetra
• Price (as of September 2, 2026): 23.00 EUR
• Sector / Industry: Health care equipment and supplies
• Index membership: not specified major index